EP1263453A4 - Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere - Google Patents

Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere

Info

Publication number
EP1263453A4
EP1263453A4 EP01939971A EP01939971A EP1263453A4 EP 1263453 A4 EP1263453 A4 EP 1263453A4 EP 01939971 A EP01939971 A EP 01939971A EP 01939971 A EP01939971 A EP 01939971A EP 1263453 A4 EP1263453 A4 EP 1263453A4
Authority
EP
European Patent Office
Prior art keywords
regulating
release
time
biologically active
active compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01939971A
Other languages
German (de)
English (en)
Other versions
EP1263453A2 (fr
Inventor
Joachim B Kohn
Deborah M Schachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of EP1263453A2 publication Critical patent/EP1263453A2/fr
Publication of EP1263453A4 publication Critical patent/EP1263453A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01939971A 1999-12-31 2001-01-02 Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere Ceased EP1263453A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17413799P 1999-12-31 1999-12-31
US174137P 1999-12-31
PCT/US2001/000030 WO2001049249A2 (fr) 1999-12-31 2001-01-02 Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere

Publications (2)

Publication Number Publication Date
EP1263453A2 EP1263453A2 (fr) 2002-12-11
EP1263453A4 true EP1263453A4 (fr) 2008-02-20

Family

ID=22634986

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01939971A Ceased EP1263453A4 (fr) 1999-12-31 2001-01-02 Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere

Country Status (5)

Country Link
EP (1) EP1263453A4 (fr)
JP (1) JP2003519164A (fr)
AU (1) AU784226B2 (fr)
CA (1) CA2396037A1 (fr)
WO (1) WO2001049249A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7326425B2 (en) 1999-12-31 2008-02-05 Rutgers, The State University Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
US8315700B2 (en) 2006-02-08 2012-11-20 Tyrx, Inc. Preventing biofilm formation on implantable medical devices
EP2114298B1 (fr) 2006-02-08 2022-10-19 Medtronic, Inc. Prothèses de type treillis temporairement raidies
US9265865B2 (en) 2006-06-30 2016-02-23 Boston Scientific Scimed, Inc. Stent having time-release indicator
US9023114B2 (en) 2006-11-06 2015-05-05 Tyrx, Inc. Resorbable pouches for implantable medical devices
MX2009004821A (es) 2006-11-06 2009-11-23 Tyrx Pharma Inc Bolsas de malla para dispositivos medicos implantables.
AU2008232682B2 (en) 2007-03-29 2013-03-21 Medtronic, Inc. Biodegradable, polymer coverings for breast implants
MX2009011785A (es) 2007-05-02 2010-03-04 Tyrx Pharma Inc Polimeros de dihidroxibenzoato y usos de los mismos.
EP2527360B1 (fr) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2630406T3 (es) 2007-10-19 2017-08-21 Sarcode Bioscience Inc. Composición y procedimientos para el tratamiento de la retinopatía diabética
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
EP2810951B1 (fr) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
US8652525B2 (en) 2008-07-10 2014-02-18 Tyrx, Inc. NSAID delivery from polyarylates
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
CA2737769C (fr) 2008-09-22 2014-02-04 Medtronic, Inc. Polyesteramides lineaires d'esters aminophenoliques
EP2437724B1 (fr) * 2009-06-01 2015-09-30 Tyrx, Inc. Compositions et méthodes pour prévenir les infections de blessures sternales
US9839628B2 (en) 2009-06-01 2017-12-12 Tyrx, Inc. Compositions and methods for preventing sternal wound infections
WO2011014859A1 (fr) * 2009-07-31 2011-02-03 Rutgers, The State University Of New Jersey Polymères biocompatibles pour dispositifs médicaux
US8409279B2 (en) 2009-10-01 2013-04-02 Lipose Corporation Breast implant implantation method and apparatus
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
JP6031033B2 (ja) 2010-08-25 2016-11-24 タイレックス・インコーポレイテッドＴｙｒｘ Ｉｎｃ． 医療デバイスの新規なコーティング
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2011326417A1 (en) 2010-11-12 2013-05-09 Tyrx, Inc. Anchorage devices comprising an active pharmaceutical ingredient
AU2012283875B2 (en) 2011-07-20 2016-05-12 Medtronic, Inc. Drug eluting mesh to prevent infection of indwelling transdermal devices
CA2879982C (fr) 2012-07-25 2020-09-01 Sarcode Bioscience Inc. Inhibiteur de lfa-1 et polymorphe de celui-ci
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014137454A1 (fr) 2013-03-07 2014-09-12 Tyrx, Inc. Procédés et compositions permettant d'inhiber l'assemblage de cellules microbiennes se liant de façon irréversible à la surface de dispositifs médicaux
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
CA2905438A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
CN106061494A (zh) 2013-10-10 2016-10-26 辛纳吉制药公司 可用于治疗阿片样物质诱导的功能障碍的鸟苷酸环化酶的激动剂
WO2015069305A1 (fr) 2013-11-08 2015-05-14 Tyrx, Inc. Compositions antimicrobiennes et procédés de prévention d'infection dans des sites d'incision chirurgicale
EP3177319A1 (fr) * 2014-08-04 2017-06-14 Janssen Sciences Ireland UC Forme posologique solide comprimée
WO2017123634A1 (fr) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations et méthodes pour traiter la rectocolite hémorragique

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587507A (en) * 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
WO1997019996A1 (fr) * 1995-11-27 1997-06-05 Rutgers, The State University Copolymeres d'un polycarbonate a base de tyrosine et de poly(oxyde d'alkylene)
WO1998036013A1 (fr) * 1997-02-18 1998-08-20 Rutgers, The State University Monomeres derives d'acides hydroxyliques et polymeres prepares a partir de ceux-ci
WO1999024107A1 (fr) * 1997-11-07 1999-05-20 Rutgers, The State University Polymeres anioniques biodegradables derives de l-tyrosine aminoacide
WO1999029758A1 (fr) * 1997-12-12 1999-06-17 Samyang Corporation Poly[acide alpha-(omega-aminoalkyl) glycolique] pour le transport d'un agent bioactif par voie tissulaire et penetration cellulaire
WO1999052962A1 (fr) * 1998-04-13 1999-10-21 Rutgers, The State University Construction de bibliotheques de copolymeres

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
JP2002536695A (ja) * 1999-02-05 2002-10-29 エイリアン・テクノロジイ・コーポレーション アセンブリを形成するための装置および方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587507A (en) * 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
WO1997019996A1 (fr) * 1995-11-27 1997-06-05 Rutgers, The State University Copolymeres d'un polycarbonate a base de tyrosine et de poly(oxyde d'alkylene)
WO1998036013A1 (fr) * 1997-02-18 1998-08-20 Rutgers, The State University Monomeres derives d'acides hydroxyliques et polymeres prepares a partir de ceux-ci
WO1999024107A1 (fr) * 1997-11-07 1999-05-20 Rutgers, The State University Polymeres anioniques biodegradables derives de l-tyrosine aminoacide
WO1999029758A1 (fr) * 1997-12-12 1999-06-17 Samyang Corporation Poly[acide alpha-(omega-aminoalkyl) glycolique] pour le transport d'un agent bioactif par voie tissulaire et penetration cellulaire
WO1999052962A1 (fr) * 1998-04-13 1999-10-21 Rutgers, The State University Construction de bibliotheques de copolymeres

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHA Y ET AL: "a one-week subdermal delivery system for l-methadone based on biodegradable microcapsules", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 7, no. 1, April 1988 (1988-04-01), pages 69 - 78, XP002143620, ISSN: 0168-3659 *

Also Published As

Publication number Publication date
JP2003519164A (ja) 2003-06-17
WO2001049249A2 (fr) 2001-07-12
AU2925501A (en) 2001-07-16
EP1263453A2 (fr) 2002-12-11
AU784226B2 (en) 2006-02-23
WO2001049249A3 (fr) 2002-01-17
CA2396037A1 (fr) 2001-07-12

Similar Documents

Publication Publication Date Title
EP1263453A4 (fr) Formulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere
EP1251864A4 (fr) Formulation pharmaceutique composee d'un melange polymere et d'un compose actif pour une liberation regulee dans le temps
NO981893D0 (no) Polymerblandingsmatriks med vedvarende frigiving for farmas÷ytisk anvendelse
MY118835A (en) Sustained release compositions and the process for their preparation
WO1998029095A3 (fr) Formulation de minicomprimes de cisapride a liberation prolongee
FR2752732B1 (fr) Forme galenique a liberation prolongee de milnacipran
FR2653338B1 (fr) Formulation pour des pansements a liberation prolongee de medicament et son utilisation.
GB2341550B (en) Gastroretentive controlled release microspheres for improved drug delivery
DK0730444T3 (da) Præparater med opretholdt frigivelse til 24-timers frigivelse af metoprolol.
DE69523438D1 (de) Orale metoprolol-dosisform des typs "einmal täglich"
FR2734483B1 (fr) Forme d'administration pharmaceutique comprenant de l'oxybutynine
EP0940796A4 (fr) Dispositif d'affichage a matrice active
NO20000284D0 (no) Tanninsyre-polymerblandinger for kontrollert frigivelse av farmasoeytiske midler, saerlig i munnhulen
FR2767479B1 (fr) Dispositif d'injection de medicament
ZA9810465B (en) Matrix pellets for greasy oily or sticky drug substances
DE59804823D1 (de) Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
PL348862A1 (en) Cosmetic composition comprising at least a film−forming polymer and at least a regulating agent
NO996161D0 (no) En kontrollert frigjoerende formulering for tungt loeselige basiske legemidler
FR2763852B1 (fr) Composition comprenant un derive de l'acide cinnamique et un polymere polyamine
BR9811582B1 (pt) compostos derivados de 4-oxo-3,5-di-hidro-4h-piridazino[4,5-b]indol-1-acetamid a, medicamento e composição farmacêutica contendo os mesmos.
IL126892A0 (en) Pharmaceutical compositions for the sustained release of insoluble active principles
FR2872044B1 (fr) Formulation pharmaceutique a base d'antibiotique sous forme microcapsulaire
FR2762213B1 (fr) Composition pharmaceutique a retention gastrique
FR2748209B1 (fr) Composition pharmaceutique a base de matrices lipophiles stabilisees pour la liberation controlee de principes actifs
IL117599A0 (en) Pharmaceutical matrix pellets tablets and composition for the preparation thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020723

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

R17P Request for examination filed (corrected)

Effective date: 20020723

A4 Supplementary search report drawn up and despatched

Effective date: 20080121

17Q First examination report despatched

Effective date: 20080718

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20110207